A problem with a supplier in India has led Mylan ($MYL) to voluntarily recall a cancer drug in Canada. The maker of generic drugs has recalled one lot of methotrexate injection after the discovery of particulate in a unit. Mylan notified Health Canada of the potential manufacturing issue after it was uncovered during an inspection by a regulator of Onco Therapies, a unit of India's Strides Arcolab and one of its suppliers. Mylan made the decision to recall the product after its own investigation found the same problem in a sample of its product. Health Canada said it is looking at other Onco Therapies products shipped to Canada to see if there are any other issues. Report